RxDoctor Payments DataLook up a doctor →

Sandeep Hindupur, MD

Interventional Cardiology · Saint Peters, MONPI 1124164066

Payments from drug & device makers

$57,997in general payments, 2019–2025

Across 499 payments — averaging $116.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$21K
  • Siemens Medical Solutions USA, Inc.$12K
  • Medtronic$4K
  • Lilly USA, LLC$4K
  • Abbott$3K
  • Z-medica, LLC$2K
  • plus $12K from 46 others

What the payments were for

  • Consulting fees$4,0847%
  • Speaking & faculty fees$23,57941%
  • Travel & lodging$17,63230%
  • Food & beverage$12,62222%
  • Education$790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,997 in reported general payments places this provider in the 70th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$115,049
Medicare patients
979
Services billed
1,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban360$459,647
XareltoRivaroxaban138$167,461
EntrestoSacubitril/Valsartan70$97,895
JardianceEmpagliflozin42$64,035
Repatha SureclickEvolocumab37$33,234
BrilintaTicagrelor36$32,357
MultaqDronedarone Hcl16$19,074
FarxigaDapagliflozin Propanediol12$16,057
Praluent PenAlirocumab17$12,602
Atorvastatin Calcium340$3,568
Metoprolol Succinate289$3,110
Prasugrel Hcl36$2,593
Metoprolol Tartrate265$2,268
Diltiazem 24hr Er (Cd)Diltiazem Hcl67$2,261
Amiodarone Hcl72$1,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$666$459,647360 claims
Johnson & JohnsonXarelto$575$167,461138 claims
NovartisEntresto$649$97,89570 claims
Boehringer IngelheimJardiance$21,185$64,03542 claims
AstraZenecaBrilinta, Farxiga$341$48,41448 claims
Sanofi-aventis U.S. LLCMultaq$140$19,07416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →